Today's Pre-Open Stock Movers

iBio, Inc. (NYSE: IBIO) 50% HIGHER; provided an update on its COVID-19 vaccine manufacturing capacity and announced that it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), one of 14 institutes in the Manufacturing USA Network.

RTI Surgical Holdings, Inc. (Nasdaq: RTIX) 29.9% HIGHER; announces a second amendment to its definitive agreement for the sale of RTI Surgical Holdings' OEM business to Montagu Private Equity LLP. Reduces the cash purchase price from $480,000,000 to $440,000,000.

Quotient Limited (NASDAQ: QTNT) 20% HIGHER; reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to complete the CE marking process and the submission of the FDA emergency use authorization for the MosaiQ COVID-19 Antibody Microarray in the next few days. Discussions with potential customers in Europe and the US are ongoing.

Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) 19.8% HIGHER; presents preclinical and initial clinical data for SNDX-5613, the Company's potent, highly selective oral menin inhibitor. The oral presentation will be featured during the New Drugs on the Horizon session at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The New Drugs on the Horizon session will take place today at 4:50 p.m. ET and features discussions of innovative small molecules and biologics that have recently entered Phase 1 clinical trials.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) 15.5% LOWER; announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by NeuBase.

F5 Networks (NASDAQ: FFIV) 12.7% HIGHER; reported Q2 EPS of $2.23, $0.28 better than the analyst estimate of $1.95. Revenue for the quarter came in at $585.6 million versus the consensus estimate of $559.04 million. F5 Networks sees Q3 2020 EPS of $1.91-$2.13, versus the consensus of $1.84. F5 Networks sees Q3 2020 revenue of $555-585 million, versus the consensus of $546.86 million.

Harmonic (NASDAQ: HLIT) 10.8% LOWER; reported Q1 EPS of ($0.10), $0.05 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $78.4 million versus the consensus estimate of $85.02 million. Withdraws FY2020 guidance.

Gaia, Inc. (NASDAQ: GAIA) 9.5% LOWER; first-quarter revenue increased 16% to $14.5 million.

IMAX Corporation (NYSE: IMAX) 8.2% HIGHER; Benchmark upgraded from Hold to Buy with a $14 price target.

Keurig Dr Pepper Inc. (NYSE: KDP) 7.5% HIGHER; reported Q1 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $2.61 billion versus the consensus estimate of $2.55 billion. Keurig Dr Pepper Inc. sees FY2020 EPS of $1.38-$1.40, versus the consensus of $1.36. The impacts and volatility of COVID-19 are expected to be significant in 2020.

Quest Diagnostics (NYSE: DGX) 7.3% HIGHER; Beginning today, individuals can purchase COVID-19 antibody testing for themselves online, without visiting a doctor's office, through QuestDirect, the consumer-initiated testing business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Morgan Stanley upgraded Quest Diagnostics (NYSE: DGX) from Equalweight to Overweight with a price target of $139.

Moderna, Inc., (Nasdaq: MRNA) 5.4% HIGHER; announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2) to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

K12, Inc. (NYSE: LRN) 5% LOWER; reported Q3 EPS of $0.22, $0.03 better than the analyst estimate of $0.19. Revenue for the quarter came in at $257.2 million versus the consensus estimate of $253.83 million. K12, Inc. sees FY2020 revenue of $1.033-1.04 billion, versus the consensus of $1.03 billion.

INOVIO (NASDAQ: INO) 5% HIGHER; announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety results expected in late June. The 40 healthy volunteers now enrolled at sites at the University of Pennsylvania in Philadelphia, PA, and a clinic in Kansas City, MO, will receive two doses of INO-4800 four weeks apart. The Phase 1 study is designed to assess the safety profile and immunogenicity of INO-4800 in support of advancing rapidly to a Phase 2/3 efficacy trial, which is planned to potentially initiate this summer.

3M Co. (NYSE: MMM) 4.9% HIGHER; reported Q1 EPS of $2.16, $0.13 better than the analyst estimate of $2.03. Revenue for the quarter came in at $8.1 billion versus the consensus estimate of $7.91 billion. Withdraws full-year 2020 guidance due to COVID-19 impact and end-market uncertainty

Amkor Technology (NASDAQ: AMKR) 4% HIGHER; reported Q1 EPS of $0.26, $0.11 better than the analyst estimate of $0.15. Revenue for the quarter came in at $1.15 billion versus the consensus estimate of $1.1 billion. Amkor Technology sees Q2 2020 EPS of ($0.13)-$0.08, versus the consensus of $0.11. Amkor Technology sees Q2 2020 revenue of $1-1.1 billion, versus the consensus of $996.15 billion.

Cognex Corp (NASDAQ: CGNX) 3.6% HIGHER; reported Q1 EPS of $0.11, $0.03 better than the analyst estimate of $0.08. Revenue for the quarter came in at $167.24 million versus the consensus estimate of $157.37 million. Provides less-specific Q2 guidance.

Universal Health (NYSE: UHS) 3.4% LOWER; reported Q1 EPS of $1.73, $0.82 worse than the analyst estimate of $2.55. Revenue for the quarter came in at $2.83 billion versus the consensus estimate of $2.92 billion.

Merck (NYSE: MRK) 2.6% LOWER; reported Q1 EPS of $1.50, $0.16 better than the analyst estimate of $1.34. Revenue for the quarter came in at $12.06 billion versus the consensus estimate of $11.46 billion. Merck sees FY2020 EPS of $5.17-$5.37, versus the consensus of $5.56. Merck sees FY2020 revenue of $46.1-48.1 billion, versus the consensus of $48.72 billion.

Pfizer (NYSE: PFE) 2.5% HIGHER; reported Q1 EPS of $0.80, $0.07 better than the analyst estimate of $0.73. Revenue for the quarter came in at $12 billion versus the consensus estimate of $11.89 billion. Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.86. Pfizer sees FY2020 revenue of $48.5-50.5 billion, versus the consensus of $49.33 billion.

Immunomedics, Inc. (NASDAQ: IMMU) 2.2% LOWER; commenced an underwritten public offering of $350,000,000 of shares of its common stock. In addition, Immunomedics expects to grant the underwriters a 30-day option to purchase up to an aggregate of an additional $52,500,000 of shares of common stock sold in connection with the offering at the public offering price.

Avnet (NASDAQ: AVT) 1.6% HIGHER; reported Q3 EPS of $0.38, $0.06 better than the analyst estimate of $0.32. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.06 billion.

Boeing Co (NYSE: BA) 1% HIGHER; will resume production of 787 aircraft at its facilities in South Carolina, with most of the staff returning by May 4.